依立替康应用于广泛期小细胞肺癌的疗效观察  

Clinical Efficacy of Irinotecan for Extensive Small-Cell Lung Cancer

作　　者：赵艳杰[1] 曹艺[1] 

机构地区：[1]北京世纪坛医院,北京市100038

出　　处：《中国医院用药评价与分析》2009年第2期136-138,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨依立替康+卡铂与口服依托泊苷+卡铂治疗初治广泛期小细胞肺癌的疗效差异。方法:两组患者分别接受IC:第1天静脉滴注卡铂(AUC=5),第1、8、15天静脉滴注依立替康[50mg.(m2)-1],21d为1周期。EC:第1～5天口服依托泊苷[120mg.(m2)-1],卡铂用法同第1组,21d为1周期。出现相关不良反应适当减量,评价两组的疗效和毒性。结果:缓解率方面IC组没有显示优势(P>0.05)。IC组PFS明显优于EC组(P<0.05)。血液学毒性方面,IC组明显低于EC组(除血小板减少外其它方面P均<0.05)。IC组腹泻发生率显著高于EC组(P<0.05)。结论:和EC组相比,IC组PFS长,血液学毒性小,但腹泻发生率较高。OBJECTIVE： To evaluate the clinical efficacy of irinotecan / carboplatin （IC） versus etoposide / carboplatin （EC） for extensive small- cell lung cancer. METHODS： Patients with extensive SCLC were assigned to receive carboplatin （AUC = 5） on day 1 by iv gtt in combination with irinotecan [50 mg·（m2）^-1, iv gtt] on day 1, 8, and 15 （IC group） or with etoposide [ 120 mg·（m2）^-1, per os] from day 1 to day 5 （EC group）, and the course of treatment was repeated in every 21 days. If side effects appeared, dosage should be reduced accordingly. The efficacy and toxicity of the two groups were evaluated. RESULTS ： IC group did not show superiority in remission rate as compared with EC group （ P 〉 0.05）, however, the PFS in IC group was significantly superior to that in EC group （ P 〈 0.05） ; the toxicity of hematology in IC group was significantly lower than in EC group （ P 〈 0.05 for all the indexes except for thrombocytopenia）, but the incidence of diarrhea in IC group was significantly higher than in EC group （ P 〈 0.05）. CONCLUSION ： Compared to EC, IC had longer PFS, lower hematological toxicity but higher incidence of diarrhea.

关 键 词：依立替康 小细胞肺癌 疗效观察 

分 类 号：R979.1[医药卫生—药品]